Who are GH Research PLC's main suppliers?

GH Research PLC (GHRS) key suppliers include: STORZ-BICKEL, STORZ-BICKEL-TUTTLINGEN. View the full supplier network at chainsifter.com/chain/GHRS.

Who are GH Research PLC's major customers?

GH Research PLC (GHRS) key customers include: ACADIA Pharmaceuticals Inc., ACADIA Pharmaceuticals Inc., ADC Therapeutics SA, ADC Therapeutics SA, Genmab A/S and 7 more. View the full customer network at chainsifter.com/chain/GHRS.

What sector is GH Research PLC in?

GH Research PLC (GHRS) operates in the general sector. ChainSifter tracks its verified supply chain relationships including suppliers, customers, and strategic partners.

GH Research PLC Supply Chain Data (GHRS): 15 Verified Relationships

2Suppliers

12Customers

1Debt Items

20Related Chains

Source-Backed Evidence Depth

GH Research PLC (GHRS) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.

16Total relationships

2Distinct source URLs

4High confidence

0.753Average confidence

2026-10-28Latest database update

ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.

GH Research PLC Suppliers

Ticker	Name	Confidence	Evidence
STORZ-BICKEL	STORZ-BICKEL	90%	For example, in current and previous clinical trials, GH001 has been vaporized using a device we purchased on the market from a single third-party manufacturer, Storz & Bickel, Tuttlingen.
STORZ-BICKEL-TUTTLINGEN	STORZ-BICKEL-TUTTLINGEN	90%	For example, in current and previous clinical trials, GH001 has been vaporized using a device we purchased on the market from a single third-party manufacturer, Storz & Bickel, Tuttlingen.

GH Research PLC Customers

Ticker	Name	Confidence	Evidence
ACAD	ACADIA Pharmaceuticals Inc.	72%	Reciprocal relationship from ACAD graph: Reciprocal relationship from GHRS graph: 1 million for the year ended December 31, 2024. This movement is primarily as a result of the translation of our asse…
ACAD	ACADIA Pharmaceuticals Inc.	72%	1 million for the year ended December 31, 2024. This movement is primarily as a result of the translation of our assets and liabilities from their denominated currencies into the functional currency …
ADCT	ADC Therapeutics SA	72%	Reciprocal relationship from ADCT graph: Reciprocal relationship from GHRS graph: Reciprocal relationship from ADCT graph: Reciprocal relationship from GHRS graph: Reciprocal relationship from ADCT g…
ADCT	ADC Therapeutics SA	72%	1 million for the year ended December 31, 2024. This movement is primarily as a result of the translation of our assets and liabilities from their denominated currencies into the functional currency …
GNMSF	Genmab A/S	72%	1 million for the year ended December 31, 2024. This movement is primarily as a result of the translation of our assets and liabilities from their denominated currencies into the functional currency …
GNMSF	Genmab A/S	72%	Reciprocal relationship from GNMSF graph: Reciprocal relationship from GHRS graph: Reciprocal relationship from GNMSF graph: Reciprocal relationship from GHRS graph: Reciprocal relationship from GNMS…
MS-PE	Morgan Stanley	72%	Reciprocal relationship from MS-PE graph: Reciprocal relationship from GHRS graph: Reciprocal relationship from MS-PE graph: Reciprocal relationship from GHRS graph: Reciprocal relationship from MS-P…
MS-PK	Morgan Stanley	72%	1 million for the year ended December 31, 2024. This movement is primarily as a result of the translation of our assets and liabilities from their denominated currencies into the functional currency …
ZLDPF	Zealand Pharma A/S	72%	Reciprocal relationship from ZLDPF graph: Reciprocal relationship from GHRS graph: 1 million for the year ended December 31, 2024. This movement is primarily as a result of the translation of our ass…
ZLDPF	Zealand Pharma A/S	72%	1 million for the year ended December 31, 2024. This movement is primarily as a result of the translation of our assets and liabilities from their denominated currencies into the functional currency …
ARDX	Ardelyx, Inc.	62%	Reciprocal relationship from ARDX graph: Reciprocal relationship from GHRS graph: Reciprocal relationship from ARDX graph: Reciprocal relationship from GHRS graph: Reciprocal relationship from ARDX g…
CONTINGENCIES-THE-GROUP	CONTINGENCIES-THE-GROUP	62%	ver which all of the specified vesting conditions are to be satisfied. Share capital and additional paid-in capital Share capital Share capital represents the nominal value of outstanding shares (see…

GH Research PLC Debt Obligations

Instrument	Description	Confidence	Evidence
GHRS-DEBT	Debt stack $432,000	90%	Market cache reports total debt of $432,000.

GH Research PLC Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for GH Research PLC.

GH Research PLC Ownership

Holder	Name	Confidence	Evidence
GHRS-OWNER-LYNX1-CAPITAL-MANAGEMENT-LP	Lynx1 Capital Management LP	90%	13F overlay lists Lynx1 Capital Management LP as top holder; 56 tracked holders.

GH Research PLC Extended Supply Chain Network

Ticker	Name	Chain Index	Hops	Relationship Types
PYXS	Pyxis Oncology, Inc.	100.00	2
ACAD	ACADIA Pharmaceuticals Inc.	100.00	1	['customer']
GNMSF	Genmab A/S	100.00	1	['customer']
STOK	Stoke Therapeutics, Inc.	100.00	2
OCSL	Oaktree Specialty Lending Corporation	100.00	2
ARDX	Ardelyx, Inc.	100.00	1	['customer']
ADCT	ADC Therapeutics SA	100.00	1	['customer']
BOLT	Bolt Biotherapeutics, Inc.	100.00	2
MS-PE	Morgan Stanley	100.00	1	['customer']
DAWN	Day One Biopharmaceuticals Inc	100.00	2
CRBP	Corbus Pharmaceuticals Holdings, Inc.	100.00	2
JNJ	Johnson & Johnson	100.00	2
ZLDPF	Zealand Pharma A/S	100.00	1	['customer']
IMTX	Immatics N.V.	100.00	2
BCAX	Bicara Therapeutics Inc.	100.00	2
GMAB	Genmab A/S	100.00	2
ENIC	Enel Chile S.A.	50.00	2
CRCL	Circle Internet Group	50.00	2
BGIN	Bgin Blockchain Limited	50.00	2
CMTG	Claros Mortgage Trust, Inc.	50.00	2

GH Research PLC Supply Chain